Navigation Links
Ultrasound can predict tumor burden and survival in melanoma patients
Date:9/23/2009

Berlin, Germany: Researchers have shown for the first time that patterns of ultrasound signals can be used to identify whether or not cancer has started to spread in melanoma patients, and to what extent. The discovery enables doctors to decide on how much surgery, if any, is required and to predict the patient's probable survival.

Dr Christiane Voit told Europe's largest cancer congress, ECCO 15 ESMO 34 [1], in Berlin today (Wednesday 23 September): "We have identified two ultrasound patterns of lymph node metastasis in melanoma patients which can identify correctly any amount of tumour cells in the sentinel lymph nodes in 75-90% of cases before proceeding to surgery on the sentinel lymph nodes."

Dr Voit, who is a dermatologist and head of the diagnostic unit at the Skin Cancer Centre at Charit Universittsmedizin Berlin, the Medical University of Berlin, Germany, said that although her research needs to be confirmed in multi-centre, randomised clinical trials, it had the potential to spare patients unnecessary surgery, especially if it was combined with ultrasound-guided fine needle biopsy of lymph nodes rather than conventional surgery.

Since 2001 Dr Voit and her colleagues in Germany and The Netherlands have included 850 melanoma patients in a prospective study to investigate the use of ultrasound in diagnosis and treatment planning. They have already demonstrated that ultrasound-guided fine needle biopsy of sentinel nodes before conventional sentinel node surgery can identify up to 65% of patients in whom the cancer has started to spread. The study presented today shows how far ultrasound patterns correlate with disease progression, tumour burden, survival and prognosis in the first 400 of these patients with stage I/II melanoma and with the longest follow-up.

Before having sentinel node surgery the patients were investigated using ultrasound, and these results were checked against the results of the subsequent surgery.
'/>"/>

Contact: Emma Mason
wordmason@mac.com
44-771-129-6986
ECCO-the European CanCer Organisation
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. New acoustic absorber to improve physiotherapy ultrasound machines
2. Ultrasound plus mammography finds more cancers, but increases false positives
3. Good Imaging Now Comes in the Worlds Smallest Ultrasound Package
4. VIDEO from Medialink and Siemens: Worlds Smallest Ultrasound Package Launches in the U.S.
5. Aloka to Unveil New ProSound Diagnostic Ultrasound System at the 17th World Congress on Ultrasound in Obstetrics and Gynecology, 7th to 11th of October 2007 in Florence, Italy
6. Transcutaneous cervical esophageal ultrasound can not substitute for 24-h pH monitoring or manometry
7. Ultrasound-guided injections help ease chronic Achilles tendon pain
8. Ultrasound Beats Blood Test for Gauging Ovarian Cancers: Study
9. Through-Wave Ultrasound: Effective, Economical and Ideal for Breast Imaging, Biopsy
10. ZONARE Surpasses 1000th Worldwide z.one Ultrasound System Shipment
11. Ultrasound Treats Localized Prostate Cancer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2009)... HealthSmart, an innovative healthcare benefit...ccessfully completed a recapitalization with Silve...r lenders. Silver Point Capital, L.P. is a privat... This recapitalization allows the Company to cont...y. , , (PRWEB) November ...
(Date:11/21/2009)...N, Nov. 21 Tonight, in ...to Senator Reid,s version of the government takeov... items included in this bill; like the public opti...nment funding for elective abortion, which is the ...ly the bill provides subsidies for private plans t...
(Date:11/21/2009)...ON, Nov. 21 A regional ...ocerciasis (river blindness) in the Americas has s... in recent years, as evidenced by a 31% decrease i...ministration in six endemic countries. Results we...e American Society of Tropical Medicine and Hygien...
(Date:11/21/2009)... Innovative medical apparel company launches m... San Clemente, Calif. (PRWEB) Nov...ough medical apparel, today announced the launch o...ica 2009, a leading international trade fair for t...edelita inaugurates its men,s collection with thre...
(Date:11/21/2009)... Linwood Group ask whether there is a secret t... , London, UK (PRWEB) Nove... to one in three of the adult UK population drinki...lcohol-related liver disease*, it is hardly a surp...itation programmes and residential centres for hel...
Breaking Medicine News(10 mins):Health News:HealthSmart Completes Recapitalization to Support Continued Growth, Daniel D. Crowley Named Chairman 2Health News:FRC: Senate Votes to Proceed with Abortion Funding Debacle 2Health News:River Blindness (Onchocerciasis) Reduced By Nearly One-Third In At-Risk Populations In Six Countries 2Health News:River Blindness (Onchocerciasis) Reduced By Nearly One-Third In At-Risk Populations In Six Countries 3Health News:River Blindness (Onchocerciasis) Reduced By Nearly One-Third In At-Risk Populations In Six Countries 4Health News:Medelita Introduces Men's Lab Coat Collection 2Health News:Medelita Introduces Men's Lab Coat Collection 3Health News:Linwood Group Reveal How to Decide whether Alcohol Rehab Centres are a Success or Not 2Health News:Linwood Group Reveal How to Decide whether Alcohol Rehab Centres are a Success or Not 3Health News:Linwood Group Reveal How to Decide whether Alcohol Rehab Centres are a Success or Not 4
...y, ALLEGAN, Mich., May 21 Perrigo Company,(Nasda...ed into a,collaborative agreement with Cobrek Phar...maceuticals Inc., a privately owned company that s... foam, a $34,million branded pharmaceutical produc...
.... (NYSE: CNO ) at the company,s annual meeting to...expiring at next year,s annual meeting;, -- A... incorporation to eliminate the plurality voti...LP as the company,s independent registered pub...
...have identified a biological explanation for the l...allergy and asthma in childhood. They will present...2008 International Conference in Toronto on Tuesda...d cord blood levels of IL-13, a Th2 type cytokine,...
...d: CRDT), a leading healthcare staffing company, h...arch 31, 2008., Revenue in the quarter was $10,57...revenue of $9,806,540 and an increase of 31% over ...urth quarter of 2007 and $1,712,150 in the first q...
... in very young children may cause some of the adve...er children and adults with the condition, accordi...r findings at the American Thoracic Societys 2008 ...st and sleep specialist who led the study at Ben-G...
...turer,of laser and light-based skin sculpting and ...he introduction of an additional fractional,device...s two new features,-- significantly higher speed, ...aster than competitive instruments, ProFractional-...
Other Medicine News:Health News:Perrigo Company Announces Collaborative Agreement for Generic Topical Products With Pentech 2Health News:Perrigo Company Announces Collaborative Agreement for Generic Topical Products With Pentech 3Health News:Perrigo Company Announces Collaborative Agreement for Generic Topical Products With Pentech 4Health News:Possible biological explanation for C-Section-linked allergies and asthma found 2Health News:Crdentia Announces 2008 First Quarter Results 2Health News:Crdentia Announces 2008 First Quarter Results 3Health News:Crdentia Announces 2008 First Quarter Results 4Health News:Crdentia Announces 2008 First Quarter Results 5Health News:Crdentia Announces 2008 First Quarter Results 6Health News:Crdentia Announces 2008 First Quarter Results 7Health News:Sciton Introduces ProFractional-XC(TM), High-Speed, Dual-Mode Fractional Laser 2
(Date:11/20/2009)..., MINNEAPOLIS, Nov. 20 B...sults for its first quarter ended September 30, 20...uted share, on revenues of $3,263,000. This compa...ted share, on revenues of $3,168,000 for the first...st quarter results, Biotel President and CEO Steve...
(Date:11/20/2009)... , PLYMOUTH MEETING, Pa., Nov. 20 /PRNewswire-U...mes article that questions why currently availabl...ancers are being ignored, ECRI Institute, an indep...ap to the evidence on Finasteride for Prevention ... November 13, 2009, New York Times article, " Dr...
(Date:11/20/2009)..., MEMPHIS, Tenn., Nov. 20 /PRNewswire-FirstCall/...s Division is pleased to announce the signing of a...tates Department of Defense that may lead to the c...revolutionize the treatment of the limbs of soldie...ar, the Defense Advanced Research Projects Agency ...
Breaking Medicine Technology:Biotel Announced Profitable First Quarter Ended September 30, 2009 2ECRI Institute Releases Roadmap to the Evidence on Finasteride for Prevention of Prostate Cancer: New Hotline Report to Aid Healthcare Decision Makers and Journalists 2ECRI Institute Releases Roadmap to the Evidence on Finasteride for Prevention of Prostate Cancer: New Hotline Report to Aid Healthcare Decision Makers and Journalists 3Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 2Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 3Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 4Proposal to reintroduce Iberian lynx on abandoned agricultural land 57527 1Proposal to reintroduce Iberian lynx on abandoned agricultural land 57527 2National new biology initiative offers potential for remarkable and far reaching benefits 9968 1National new biology initiative offers potential for remarkable and far reaching benefits 9968 2National new biology initiative offers potential for remarkable and far reaching benefits 9968 3The Vitality Group Joins Efforts to Improve Health of U S Workforce 57525 1The Vitality Group Joins Efforts to Improve Health of U S Workforce 57525 2
...nation with CRESTOR (rosuvastatin calcium) Improv...ety Consistent with Monotherap...hat in patients with multiple lipid problems, Abbo...ed with AstraZeneca,s CRESTOR(R) (rosuvastatin,cal...onding monotherapy in,treating all three key lipid...
...Data Reported Trial Enrollment Advanc...., May 31 Sunesis,Pharmaceuticals, Inc. (Nasdaq: ...from the company,s ongoing Phase 2 clinical trial ... SNS-595), in platinum-resistant ovarian,cancer pa...cology (ASCO),Annual Meeting in Chicago, Illinois....
Other Medicine Technology:Phase III Study of Abbott's Investigational TriLipix(TM) in Combination With AstraZeneca's CRESTOR(R) Meets Primary Endpoints on Key Lipids 2Phase III Study of Abbott's Investigational TriLipix(TM) in Combination With AstraZeneca's CRESTOR(R) Meets Primary Endpoints on Key Lipids 3Phase III Study of Abbott's Investigational TriLipix(TM) in Combination With AstraZeneca's CRESTOR(R) Meets Primary Endpoints on Key Lipids 4Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting 2Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting 3Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting 4Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting 5
Prechopper curved
Medina Irrigating Nucleus Chopper
Rosen Irrigating Nucleus Chopper
Agarwal Irrigating Nucleus Chopper
Medicine Products: